Market Dashboard
- You are here:
- Home
- Markets
- Market Dashboard
- Sun Pharmaceutical Industries Ltd.
NSE Symbol: | BSE Code: | ISIN: | Sector:
- Add to Portfolio
- Add to Watchlist
- Add to Alert
- Add to Message
| Change | Change % |
| 14.10 | 1.25% |
Updated:27 Sep, 2023, 15:57 PM IST |
|
| Change | Change % |
| 15.35 | 1.36% |
Updated:27 Sep, 2023, 16:01 PM IST |
|
Day's Range
52 Wk Range
Compare Price performance of vs. Peer Companies
From sector
Compare with Peers on Key Fundamentals and Financials
- SUNPHARMA
1.36% - DIVISLAB
0.35% - CIPLA
1.43% - DRREDDY
0.49% - CADILAHC
1.23% - AUROPHARMA
2.61% - LUPIN
2.06% - ABBOTINDIA
0.07% - ALKEM
0.69% - BIOCON
1.20% - TORNTPHARM
1.12% - GLAXO
-0.14% - GLENMARK
1.78% - PEL
0.11% - PFIZER
-0.23% - SANOFI
0.43% - NATCOPHARM
0.96% - AJANTPHARM
3.20% - APLLTD
0.50% - IPCALAB
1.99% - ERIS
1.01% - JBCHEPHARM
0.25% - ASTRAZEN
0.26% - GRANULES
3.88% - MERCK
1.77% - CAPLINLABS
0.75% - FDC
2.56% - NEULANDLAB
-0.15% - STAR
-1.78% - MARKSANS
1.13%
's Latest Research Report
| Brokerage/Analyst | Report Date | Call | Price@Call | Target | Current Status | Report |
|---|---|---|---|---|---|---|
| Emkay Global - |
14-01-2022 | Hold | 861.30 | 775.00 | Target Hit | Details |
| Emkay Global - |
06-11-2021 | Hold | 795.35 | 775.00 | Target Hit | Details |
| Nomura - |
30-03-2020 | Buy | 333.65 | 525.00 | Target Hit | Details |
| Nomura - |
05-02-2020 | Buy | 425.30 | 525.00 | Closed | Details |
| HDFC Securities - |
14-08-2019 | Buy | 417.05 | 545.00 | Closed | Details |
More from Research Reports »
Sun Pharma Inds.'s Key Fundamentals
| Parameter | Values |
|---|---|
| Market Cap (in ₹ Cr.) | 2,73,511.63 |
| Earning Per Share (EPS TTM) (₹) | -3.27 |
| Price To Earnings (P/E) Ratio | -348.61 |
| Book Value Per Share (₹) | 82.40 |
| Price To Books (P/B) Ratio | 13.83 |
| EBIT Margin (%) | -1.66 |
| PAT Margin (%) | -6.22 |
| ROCE (%) | -0.49 |
| PAT Growth (%) | -2065.46 |
| Total Debt to Equity (D/E) Ratio | 0.35 |
More from Key Fundamentals »
Sun Pharma Inds.'s Financial Summary
| Parameter | MAR'18 (₹ Cr.) |
MAR'17 (₹ Cr.) |
YoY %Change |
|---|---|---|---|
| Balance Sheet: | |||
| Share Capital | 239.93 | 239.93 | 0.00% |
| Total Non-Current Liabilities | 2,248.68 | 2,234.54 | 0.63% |
| Total Current Liabilities | 12,243.49 | 10,962.65 | 11.68% |
| Total Liabilities | 34,262.27 | 34,209.66 | 0.15% |
| Total Non-Current Assets | 27,354.75 | 27,821.47 | -1.68% |
| Currents Investments | 44.76 | 40.01 | 11.87% |
| Cash and Bank | 155.27 | 170.28 | -8.81% |
| Total Current Assets Excluding Current Investments | 6,862.76 | 6,348.18 | 8.11% |
| Total Assets | 34,262.27 | 34,209.66 | 0.15% |
| Profit and Loss: | |||
| Gross Sales | 7,947.60 | 7,793.20 | 1.98% |
| Net Sales | 7,923.84 | 7,683.96 | 3.12% |
| PBIDT (Excl OI) | 1.42 | -60.65 | -102.34% |
| PAT | -494.59 | -22.84 | 2065.46% |
More from Financial Summary »
Sun Pharma Inds.'s Shareholding Pattern
| Description | Percent of Share (%) |
|---|---|
| Promoters | 63.72 |
| Individuals | 5.26 |
| Institutions | 5.52 |
| FII | 19.97 |
| Govt. | 0.00 |
| Others | 5.53 |
More from Holding Pattern »
Sun Pharma Inds. held by Mutual Fund Schemes
More from Mutual Fund Holding »
's Futures and Options Quotes
| Contract Expiry Date |
Type | Current price | Change | Change % | Premium / Discount |
|---|---|---|---|---|---|
| No Records Found! | |||||
More from Futures and Options Quotes »
Sun Pharmaceuticals Industries is a private sector pharmaceuticals company.
Sun Pharmaceuticals Industries manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. Headquartered in Mumbai, Sun Pharmaceuticals Industries registered a revenue of Rs 7,806.70 crore in FY17. Sun Pharmaceuticals Industries is the world's fourth largest specialty generic pharmaceuticals company and a provider of medicines in over 150 countries. Sun Pharmaceuticals Industries is among the top 10 consumer healthcare companies in India, Romania, Nigeria and Myanmar. Its key focus markets comprise India, Russia, Romania, Nigeria, South Africa and Myanmar. Sun Pharma's R&D unit comprises about 2,000 scientists and investments of approximately 8 per cent of annual revenues. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across six continents, R&D centres across the globe and a workforce of more than 30,000 comprising over 50 nationalities. As of September 2017, Sun Pharma promoters held a 54.38 per cent stake in the company, while the remaining 45.62 per cent was with the public.
Sun Pharma shares
Sun Pharmaceuticals Industries shares trade with symbol SUNPHARMA on stock exchanges BSE and NSE.
Sun Pharmaceuticals Industries' key focus areas include CNS, dermatology, cardiology, oncology and ophthalmics. The pharma company has a comprehensive basket of 584 ANDAs, 41 NDAs and 1 BLA filed and 427 ANDAs and 36 NDAs approved across multiple therapies. In FY17, its key contributors to revenues included Imatinib Mesylate Tablets.
History
Sun Pharmaceutical Industries was founded in 1983 with a manufacturing plant in Vapi, Gujarat. Sun Pharma has grown to become India's largest and most valuable pharmaceutical company by market capitalisation with global revenues of over $4.5 billion.
BackgroundSun Pharmaceuticals Industries completed the merger with Ranbaxy in 2015 - its largest acquisition. In April 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth $4-billion that included a debt of $800 million.
Registered office
SPARC, Tandalja, Vadodara, Gujarat-390020